{"id":"NCT02058589","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant","officialTitle":"Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-20","primaryCompletion":"2016-05-11","completion":"2017-04-13","firstPosted":"2014-02-10","resultsPosted":"2018-08-01","lastUpdate":"2018-08-01"},"enrollment":265,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster vaccine GSK1437173A","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"GSK1437173A Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.","primaryOutcome":{"measure":"Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity","timeFrame":"At Month 2.","effectByArm":[{"arm":"GSK1437173A Group","deltaMin":97,"sd":null},{"arm":"Control Group","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":25},"locations":{"siteCount":34,"countries":["Belgium","Canada","Czechia","Finland","Italy","Panama","South Korea","Spain","Taiwan"]},"refs":{"pmids":["30843046"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":132},"commonTop":["Pain","Fatigue","Myalgia","Headache","Gastrointestinal disorder"]}}